Lancet Reg Health Am 2024 (Jan 8): 29: 100661

Table 1.

NIH spending and prevalence for selected diseases, 2019.

Disease area	DALYs	Funding ($M)	U.S. prevalence		Spending per patient ($)
Disease area	DALYs	Funding ($M)	Proportion^a	Number	Spending per patient ($)
Cardiovascular	17,266,977	2394	12.75%	39,669,218	60.35
Cancer	16,651,972	6520	8.50%	26,448,947	246.51
Injuries	10,129,022	897	36.25%	112,745,086	7.96
Musculoskeletal	9,984,897	351	40.96%	127,411,125	2.75
Drug use disorders	6,121,628	1621	3.44%	10,699,858	151.50
Low back pain	5,697,152	170	16.75%	52,105,428	3.26
COPD	5,021,538	112	6.48%	20,147,917	5.56
Diabetes	4,461,171	1099	12.49%	38,858,416	28.28
Lung cancer	4,186,491	419	0.14%	444,083	943.52
Hearing loss	2,187,374	163	22.73%	70,709,407	2.31
Neck pain	2,043,518	2	6.81%	21,184,349	0.09
Alzheimer's	2,026,882	2398	1.58%	4,902,695	489.12
Osteoarthritis	1,986,343	85	16.67%	51,865,889	1.64
Anxiety disorders	1,872,338	233	6.51%	20,241,173	11.51
HIV	415,325	3037	0.56%	1,743,128	1742.27
Rheumatoid arthritis	257,884	94	0.52%	1,622,773	57.93
Multiple sclerosis	211,385	111	0.13%	409,217	271.25

Funding values are represented as dollars in millions and rounded. Prevalence percentages in the table are calculated as a proportion of the total cases (311,050,916) and are presented alongside the actual number of cases. Spending per Patient ($) is determined by dividing funding (in millions and rounded) by the number of cases in 2019 U.S. prevalence.
Abbreviations:
DALY = disability-adjusted life year;
COPD = chronic obstructive pulmonary disease.
The denominator utilized for prevalence is 311,050,916.